Zydus Lifesciences US arm secures USFDA nod for Sugammadex Injection
The drug will be manufactured at the group’s injectables manufacturing facility at Jarod, India.
Ahmedabad: Zydus Lifesciences Limited's (formerly known as Cadila Healthcare Limited) U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has received tentative approval from the United States Food and Drug Administration (USFDA) to market Sugammadex Injection USP 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL), Single-Dose Vial (US RLD: Bridion).
Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery.
The drug will be manufactured at the group's injectables manufacturing facility at Jarod, India.
Sugammadex Injection had annual sales of USD 772 mn in the United States according to IQVIA MAT July 2022. The group now has 323 approvals and has so far filed over 428* ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Lifesciences US arm bags USFDA nod for schizophrenia drug Cariprazine
Zydus group is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.
Zydus' global business has a strong presence in the regulated markets of the US, Europe (France and Spain) and in the high profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide.
